Flecainide is an IC antiarrhythmic drug (AAD) that received in 1984 Food and Drug Administration approval for the treatment of sustained ventricular tachycardia (VT) and subsequently for rhythm control of atrial fibrillation (AF). Currently, flecainide is mainly employed for sinus rhythm maintenance in AF and the treatment of idiopathic ventricular arrhythmias (IVA) in absence of ischaemic and structural heart disease on the basis of CAST data. Recent studies enrolling patients with different structural heart diseases demonstrated good effectiveness and safety profile of flecainide. The purpose of this review is to assess current evidence for appropriate and safe use of flecainide, 30 years after CAST data, in the light of new diagnostic and therapeutic tools in the field of ischaemic and non-ischaemic heart disease.
Flecainide in ventricular arrhythmias. from old myths to new perspectives / Lavalle, C.; Trivigno, S.; Vetta, G.; Magnocavallo, M.; Mariani, M. V.; Santini, L.; Forleo, G. B.; Grimaldi, M.; Badagliacca, R.; Lanata, L.; Ricci, R. P.. - In: JOURNAL OF CLINICAL MEDICINE. - ISSN 2077-0383. - 10:16(2021). [10.3390/jcm10163696]
Flecainide in ventricular arrhythmias. from old myths to new perspectives
Lavalle C.
;Magnocavallo M.;Mariani M. V.;Badagliacca R.;
2021
Abstract
Flecainide is an IC antiarrhythmic drug (AAD) that received in 1984 Food and Drug Administration approval for the treatment of sustained ventricular tachycardia (VT) and subsequently for rhythm control of atrial fibrillation (AF). Currently, flecainide is mainly employed for sinus rhythm maintenance in AF and the treatment of idiopathic ventricular arrhythmias (IVA) in absence of ischaemic and structural heart disease on the basis of CAST data. Recent studies enrolling patients with different structural heart diseases demonstrated good effectiveness and safety profile of flecainide. The purpose of this review is to assess current evidence for appropriate and safe use of flecainide, 30 years after CAST data, in the light of new diagnostic and therapeutic tools in the field of ischaemic and non-ischaemic heart disease.| File | Dimensione | Formato | |
|---|---|---|---|
|
Lavalle_Flecainide_2021.pdf
accesso aperto
Tipologia:
Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza:
Creative commons
Dimensione
2.69 MB
Formato
Adobe PDF
|
2.69 MB | Adobe PDF |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
